Todd Simpson Net Worth

The estimated Net Worth of Todd E Simpson is at least $61.2 Milione dollars as of 21 September 2023. Mr. Simpson owns over 80 units of Seagen Inc stock worth over $29,459,546 and over the last 19 years he sold SGEN stock worth over $27,293,535. In addition, he makes $4,490,090 as Chief Financial Officer at Seagen Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Simpson SGEN stock SEC Form 4 insiders trading

Todd has made over 54 trades of the Seagen Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he sold 80 units of SGEN stock worth $16,520 on 21 September 2023.

The largest trade he's ever made was exercising 95,000 units of Seagen Inc stock on 5 September 2012 worth over $1,109,600. On average, Todd trades about 14,620 units every 53 days since 2005. As of 21 September 2023 he still owns at least 128,723 units of Seagen Inc stock.

You can see the complete history of Mr. Simpson stock trades at the bottom of the page.

Todd Simpson biography

Todd E. Simpson CPA serves as Chief Financial Officer of the Company. Previously, Mr. Simpson served from October 2001 to October 2005 as Vice President, Finance & Administration and Chief Financial Officer of Targeted Genetics Corporation, a biotechnology company. From January 1996 to October 2001, Mr. Simpson served as Vice President, Finance & Administration and CFO of Aastrom Biosciences, Inc., a biotechnology company. From August 1995 to December 1995, he served as Treasurer of Integra LifeSciences Corporation, a biotechnology company, which acquired Telios Pharmaceuticals, Inc., in August 1995. From 1992 until its acquisition by Integra, he served as Vice President of Finance and CFO of Telios and in various other finance-related positions. Mr. Simpson is a certified public accountant (inactive), and from 1983 to 1992 he practiced public accounting with the firm of Ernst & Young LLP. Mr. Simpson currently serves on the board of directors of Neoleukin Therapeutics, Inc., a publicly-traded biotechnology company. Mr. Simpson received a B.S. in Accounting and Computer Science from Oregon State University.

What is the salary of Todd Simpson?

As the Chief Financial Officer of Seagen Inc, the total compensation of Todd Simpson at Seagen Inc is $4,490,090. There are 2 executives at Seagen Inc getting paid more, with Clay Siegall having the highest compensation of $14,521,500.

How old is Todd Simpson?

Todd Simpson is 59, he's been the Chief Financial Officer of Seagen Inc since 2005. There are 9 older and 8 younger executives at Seagen Inc. The oldest executive at Seagen Inc is Marc Lippman, 75, who is the Independent Director.

Insiders trading at Seagen Inc

Over the last 22 years, insiders at Seagen Inc have traded over $729,924,224 worth of Seagen Inc stock and bought 35,347,908 units worth $1,433,871,526 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Felixbaker Julian Baker Bro... e Brothers Life Sciences Capi.... On average, Seagen Inc executives and independent directors trade stock every 8 days with the average trade being worth of $18,157,295. The most recent stock trade was executed by David R Epstein on 10 November 2023, trading 10,620 units of SGEN stock currently worth $2,262,166.

What does Seagen Inc do?

seattle genetics, co-founded by clay siegall, is a biotechnology company leading the field of antibody-drug conjugates (adcs) for the treatment of cancer. our technology is designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. our lead program, adcetris® (brentuximab vedotin), is the first in a new class of adcs and, in collaboration with takeda pharmaceutical company limited, is approved in more than 55 countries. to expand on the adcetris opportunity, we are conducting a broad clinical development program to evaluate its therapeutic potential in a range of other lymphoma and non-lymphoma settings. seattle genetics is also advancing a robust pipeline of clinical-stage programs, including sgn-cd19a, sgn-cd33a, sgn-liv1a, sgn-cd70a, asg-22me, asg-15me and sea-cd40. seattle genetics has collaborations for its adc technology with a number of leading biotechnology and pharmaceutical companies, including abbvie, agensys

Complete history of Mr. Simpson stock trades at Seagen Inc e Neoleukin Therapeutics

Seagen Inc executives and stock owners

Seagen Inc executives and other stock owners filed with the SEC include:

• Clay Siegall,
  Chairman of the Board, President, Chief Executive Officer
• Roger Dansey,
  Chief Medical Officer
• Todd Simpson,
  Chief Financial Officer
• Jean Liu,
  Executive Vice President - Legal Affairs, General Counsel, Corporate Secretary
• Vaughn Himes,
  Chief Technical Officer
• Dr. Clay B. Siegall,
  Co-Founder, Chairman, Pres & CEO
• Dr. Roger D. Dansey M.D.,
  Chief Medical Officer & Interim CEO
• Jean I. Liu,
  Gen. Counsel, Exec. VP of Legal Affairs & Corp. Sec.
• Jean I. Liu J.D., M.S.,
  Chief Legal Officer
• Charles R. Romp,
  Exec. VP of Commercial U.S.
• Todd E. Simpson,
  Chief Financial Officer
• Felix Baker,
  Lead Independent Director
• David Gryska,
  Independent Director
• John Orwin,
  Independent Director
• Nancy Simonian,
  Independent Director
• Alpna Seth,
  Independent Director
• Daniel Welch,
  Independent Director
• Marc Lippman,
  Independent Director
• Ted Love,
  Director
• David Caouette,
  VP of Corp. Communications
• Dr. Vaughn B. Himes,
  Chief Technical Officer
• Christopher P. Pawlowicz,
  Exec. VP of HR
• Matt Skelton,
  VP of Marketing
• Natasha A. Hernday,
  Exec. VP of Corp. Devel. & Alliance Management
• Nancy Whiting B.Sc., Pharm.D.,
  Exec. VP of Corp. Strategy, Alliances & Communications
• Peggy Pinkston,
  VP of Investor Relations
• Bros. Advisors Lp Baker Bro...,
  
• Bros. Advisors Lp Baker Bro...,
  
• Felixbaker Julian Baker Bro...,
  
• Srinivas Akkaraju,
  Director
• Eric Dobmeier,
  Vice President,
• Bros. Advisors Lp667, L.P.B...,
  
• Sandra M Swain,
  
• Morgan Partners Bhca Lpjpmp...,
  
• / Tisch Capital (Gp), Llcba...,
  
• Biotech Capital (Gp), Llcba...,
  
• Robin G Taylor,
  Chief Commercial Officer
• Felix667, L.P.Baker Julian ...,
  
• John Peter Mclaughlin,
  Director
• Felix Baker,
  Director
• Morris Rosenberg,
  SVP, Development
• Bruce J. Seeley,
  EVP, Commerical
• Felix667, L.P.Baker Brother...,
  
• Thomas C Reynolds,
  Chief Medical Officer
• Christopher S. Boerner,
  SVP, Commercial
• Brothers Life Sciences Capi...,
  
• Capital (Gp), Llcbaker Juli...,
  
• Holdings, Inc.H&Q Employee ...,
  
• Bros. Capital (Gp), Llcbake...,
  
• Bros. Advisors Lp667, L.P.B...,
  
• Darren S Cline,
  SVP, Commercial
• Morgan Partners Bhca Lpjpmp...,
  
• Felixbaker Julian Baker Bro...,
  
• Franklin M Berger,
  Director
• Morgan Partners Bhca Lp Jp,
  10% owner
• Daniel Floyd Jr Hoth,
  Director
• Morgan Partners Bhca Lpjpmp...,
  
• Morgan Partners Bhca Lpjpmp...,
  
• Jonathan Gallen,
  10% owner
• Management Partners Vi Llcd...,
  
• Pamela A Trail Smith,
  Chief Scientific Officer
• Brothers Life Sciences Capi...,
  
• Biotech Capital Ii Gp Llcba...,
  
• Morgan Partners Bhca Lpjpmp...,
  
• Morgan Partners Bhca Lpjpmp...,
  
• Biotech Capital Ii (Z) (Gp)...,
  
• Amy Sing,
  Sr. Director Medical Affairs
• Michael Powell,
  Director
• Biotech Capital Iii (Z) (Gp...,
  
• Tim Carroll,
  CFO
• Investment Llc Cascade,
  
• Douglas Southern,
  Director
• Karl Erik Hellstrom,
  Director
• Michael Mcdonald,
  Chief Medical Officer
• Morgan Partners Bhca Lpjpmp...,
  
• Peter Senter,
  Vice President, Chemistry
• H Perry Fell,
  Chairman
• Bros. Advisors Lp Baker Bro...,
  
• Bros. Advisors Lp667, L.P.B...,
  
• David R Epstein,
  CEO
• Charles R Romp,
  EVP, Commercial U.S.